Alternative Data for NovoCure
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 49 | Sign up | Sign up | Sign up |
| Sentiment | 53 | Sign up | Sign up | Sign up |
| Webpage traffic | 21,000 | Sign up | Sign up | Sign up |
| Employee Rating | 64 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 11 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,379 | Sign up | Sign up | Sign up |
| X Followers | 2,722 | Sign up | Sign up | Sign up |
| X Mentions | 6 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 45 | Sign up | Sign up | Sign up |
| Linkedin Employees | 1,476 | Sign up | Sign up | Sign up |
About NovoCure
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma.
| Price | $13.05 |
| Target Price | Sign up |
| Volume | 975,900 |
| Market Cap | $1.51B |
| Year Range | $10.9 - $19.4 |
| Dividend Yield | 0% |
| Analyst Rating | 83% buy |
| Earnings Date | February 26 '26 |
| Industry | Medical & Dental Instruments |
In the news
 |
NovoCure Limited (NVCR) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 14 - SeekingAlpha |
 |
Why NovoCure Is Failing To Disrupt NSCLCJanuary 12 - SeekingAlpha |
 |
NovoCure: 2026 Pipeline Outlook Makes This Stock A Speculative BuyJanuary 1 - SeekingAlpha |
$7.87 Bn Glioblastoma Multiforme Treatment Market Forecast to 2033January 21 - GlobeNewswire |
|
Glioblastoma Multiforme Treatment Market to Worth Over US$ 6.1 Billion by 2033 | Astute AnalyticaJanuary 19 - GlobeNewswire |
|
 |
Novocure price target lowered by $3 at H.C. Wainwright, here's whyJanuary 13 - Thefly.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 167M | 45M | 122M | -37M | -26M | -0.330 |
| Q2 '25 | 159M | 41M | 117M | -40M | -36M | -0.360 |
| Q1 '25 | 155M | 39M | 116M | -34M | -35M | -0.310 |
| Q4 '24 | 161M | 33M | 128M | -66M | -11M | -0.610 |
| Q3 '24 | 155M | 35M | 120M | -31M | -30M | -0.280 |
Insider Transactions View All
| Cordova Ashley filed to buy 437,569 shares at $12.2. September 8 '25 |
| Brackmann Christoph filed to buy 141,150 shares at $11.5. July 30 '25 |
| Brackmann Christoph filed to buy 131,150 shares at $11.6. July 30 '25 |
| Scannell Timothy J filed to sell 6,018 shares at $17.3. June 4 '25 |
| HILLEMAN JERYL L filed to sell 5,591 shares at $17.3. June 4 '25 |
Similar companies
Read more about NovoCure (NVCR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - NovoCure
The Market Cap of NovoCure is $1.51B.
NovoCure will report its next earnings on February 26 '26.
Currently, the price of one share of NovoCure stock is $13.05.
The NVCR stock price chart above provides a comprehensive visual representation of NovoCure's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling NovoCure shares. Our platform offers an up-to-date NVCR stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, NovoCure (NVCR) does not offer dividends to its shareholders. Investors interested in NovoCure should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of NovoCure are Align Technology, Dentsply, LeMaitre Vascular, iRhythm Technologies, and Danaher.
